Thursday, May 8, 2025

Latest

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study of otenaproxesul because it breached the threshold for the number of patients exhibiting liver transaminase elevations. Then, last week, Antibe provided an update following a full scientific and strategic review. The company is now pivoting from a focus on osteoarthritis to post-operative pain, with the details of the program being few and far between in the news release.

Antibe Therapeutics currently has 6 analysts covering the stock with an average 12-month price target of C$5.58, or a 475% upside. Out of the 6 analysts, 4 have buy ratings and 2 have hold ratings. The street high sits at $20.60 while the lowest comes in at $1.20.

Canaccord Genuity lowered their 12-month price target after the news, bringing it to C$1.20 from C$5 while also lowering the stock to hold from a speculative buy rating. This price target cut reflects Canaccord removing otenaproxesul from their valuation since the full details of the program have not been outlined.

With the pivot, Canaccord believes that the osteoarthritis program is very uncertain to be resumed, they previously stated that they were hopeful that the company could get a new program up at a 75 mg dose rather than the 100 mg dose that got paused. But they now say “given the occurrence of LTEs in one patient at this dose, there is no reason for ATE to resume the study.”

As for the pivot to post-operative pain, Canaccord warns “NSAIDs are challenged by their GI safety profile, while opioids pose the dangerous risk of dependency.” They believe that Antibe could skip straight to a Phase 2 trial but management has elected to do some Phase 1 PK/PD studies starting in January 2022.

With the companies $60 billion balance sheet, management has stated that they will be able to fund fully the development. While Canaccord writes, “We believe ATE could need cash sooner should it decide to also progress any of its preclinical programs.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Related News

Hecla Mining: Canaccord Reduces Price Target To $5.75 Following Earnings

Thursday, Hecla Mining (NYSE: HL) reported their fourth quarter and full year 2020 financial results....

Saturday, February 20, 2021, 02:34:00 PM

Organigram: Analysts Upgrade Targets Following BAT Investment

On March 9th, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) announced that they received a C$221...

Sunday, March 14, 2021, 06:32:00 PM

Aphria: PI Financial Raises Price Target, Canaccord Reiterates Target

Last week, Aphria Inc (TSX: APHA) (NASDAQ: APHA) reported their year-end and fourth-quarter financial statements....

Sunday, August 2, 2020, 01:30:00 PM

Cameco: Canaccord Refers To Firm As “Go-To” Name For Uranium Exposure

On February 9th, Cameco (TSX: CCO) reported its full-year 2021 financial results. The company reported...

Saturday, February 12, 2022, 02:03:00 PM

BMO Lifts Starbucks Price Target After Earnings Beat

Starbucks (NASDAQ: SBUX) reported their fiscal third quarter results on July 27. The company beat...

Tuesday, August 3, 2021, 04:52:00 PM